Skip to content
Therapy But Better – Lifestyle
Author:
SAB Biotherapeutics, Inc.
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
March 17, 2026
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
March 17, 2026
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
March 10, 2026
←
Previous Page
1
2